Skip to main content


Cardiac Resynchronization Therapy Defibrillator
Model G547 and Model G447

play icon
Video on RESONATE Family of ICDs and CRT-Ds.

Innovative technology, powerful insights.

Comprehensive, novel technology in our RESONATE CRT-Ds helps physicians to identify heart failure early and improve CRT response in most patients. And they are fueled by the longest-lasting battery technology available, substantially reducing major complications and costs associated with battery replacement.1

In addition, comprehensive shock polarity options are available today and for the future.

Key Resources


Product Details

Identify heart failure decompensation, increase CRT response, reduce costs, and improve quality of life in heart failure patients with our RESONATE family of implantable CRT-Ds (cardiac resynchronization therapy defibrillators).

  • Boston Scientific devices are unique in providing both the option to choose the initial shock polarity and the capability to invert shock polarity during a series of shocks
  • HeartLogic™ Heart Failure Diagnostic can predict heart failure events weeks in advance with minimal alerts2
  • SmartCRT™ Technology provides customized programming to obtain CRT response in most patients3
  • EnduraLife™ Battery Technology extends device longevity (up to 13.2 years even with MultiSite Pacing turned on)* 
  • RightRate™ Minute Ventilation is the only sensor clinically proven to restore chronotropic competence4 (available only in RESONATE HF) 

Download the RESONATE ICD & CRT-D informational brochure


Clinical Data


Investigated the clinical integration and safety of the FDA-approved HeartLogic(TM) Heart Failure Diagnostic in the management of patients with heart failure9:

  • HeartLogic was safely integrated into clinical care
  • Early treatment augmentation was associated with more rapid recovery of the HeartLogic index compared to patients with no change in treatment following an alert
  • 67% reduction in heart failure hospitalizations compared to pre-study9

Read the MANAGE-HF clinical trial summary 



The SMART-MSP clinical trial exceeded both its end points:

  • Safety Endpoint: The MultiSite Pacing (MSP) feature-related complication-free rate at 180 days post MSP on is 99%
  • Effectiveness Endpoint: 51% of the non-responders at 6 months converted to responders at 12 months3

Read the SMART-MSP clinical trial summary



The NAVIGATE X4 trial was a prospective, non-randomized, multi-center, single-arm, clinical study. With 764 patients in 88 implant centers.

  • 50% of ACUITY X4 leads were placed in 6 minutes or less and required no reoperations due to pacing capture or thresholds
  • 77.3% of ACUITY X4 Spiral leads were programmed with a proximal electrode as the pacing cathode5

Read the NAVIGATE X4 clinical trial data

Preventing sudden cardiac death

Boston Scientific devices have provided meaningful shock polarity features since 1995.  All of our transvenous ICDs and CRT-Ds available to implant provide 8 shocks in the VF zone, safely support programmable shock polarity while automatically inverting polarity in a series of shocks.   
Table with specs
Watch video

How we compare to our competitors

The 8-year product performance reports show that CRT-Ds with EnduraLife Technology have greater longevity than comparable devices.6-8

Boston Scientific

CRT-Ds still in service6


 Viva™ XT CRT-Ds7 still in service


Viva Quad XT CRT-D8

Key features

RESONATE X4 and RESONATE HF are Boston Scientific’s most technically advanced CRT-Ds available with the following features:

HeartLogic Heart Failure Diagnostic, SmartCRT Technology, EnduraLife Battery Technology, ImageReady MR-Conditional Systems, and RightRate Minute Ventilation (available only with RESONATE HF).

HeartLogic Heart Failure Diagnostic

Predict potential heart failure events weeks in advance with HeartLogic.

Personalize cardiac care using the patient’s response to arrhythmic and pacing changes. Studies with HeartLogic devices have resulted in 67% reduction in heart failure related hospitalizations.9

Learn more about HeartLogic

SmartCRT Technology

Personalize CRT therapy to each patient for the most optimized outcomes.

SmartCRT helps you maximize patient response to CRT therapy by optimizing where, when, and how to pace.  

Learn more about SmartCRT

RightRate Minute Ventilation

The only sensor clinically proven to restore chronotropic competence and maintain healthy heart rate variability.10

RightRate dual sensor adapts to changes in movement and respiration, regulating the patient’s ability to increase their heart rate during exercise or other everyday activities. It’s directly correlated with the patient’s breathing instead of relying on an accelerometer only. 

Available only with RESONATE HF CRT-D. 

Learn more about RightRate

EnduraLife Battery Technology

Industry-leading longevity without compromising patient care.

CRT-D devices with EnduraLife have up to 13.3 years projected longevity*, giving you the clinical freedom to make programming decisions that optimize therapy for the patient, not the device.

Fewer major complications. Better for patients. 

Learn more about EnduraLife

ImageReady MR-Conditional systems

ImageReady MR-Conditional systems make MRIs possible for heart failure patients.

Patients can safely get Full Body MRI scans at 1.5T or 3T with ImageReady MR-Conditional devices without exclusion zone, scan duration, or patient height restrictions.11,12

ImageReady is compatible with the RESONATE X4 and RESONATE HF CRT-Ds. 

Learn more about ImageReady

Product specifications

Mechanical specifications
ModelTypeSize (cm)
(W x H x D)
Connector Type
G547 (HF)X4 CRT-D5.37 x 8.18 x 0.9973.832.5RA: IS-1; RV: DF4; LV: IS4
X4 CRT-D5.37 x 8.18 x 0.9973.832.5RA: IS-1; RV: DF4; LV: IS4

Longevity Information

The following tables represent sample pulse generator life expectancy estimation (implant to explant) with EnduraLife batteries as provided in product labeling. For specific programmable parameter ranges, refer to product labeling at, or contact Boston Scientific technical services or your local representative.

Projected longevitya Ventricular
RA/RV LV LVbd 500Ω with LATITUDE™b 700Ω with
RS, or HFSSc
MultiSite Pacing Off
Typical programmed setting BiV 2.5 V 3.0 V Off 9.7 10.5 11.3
Maximum labeled longevity LV-Only 2.0 V / Off 2.0 V Off 12.9 13.2 14.7
MultiSite Pacing On
Typical programmed setting BiV MSP 2.5 V 3.0 V 3.0 V 8.2 9.1 9.7
Maximum labeled longevity LV-Only MSP 2.0 V / Off 2.0 V 2.0 V 11.5 12.1 13.3
  • Assumes 70 PPM LRL; DDDR mode; 0.4 ms Pulse Width (RA, RV, LV); sensors On, Heart Failure Sensor Suite On.
  • Projected longevity is calculated assuming 2 maximum energy charging cycles per year, including automatic capacitor reforms and therapeutic shocks. These calculations also assume 3-channel EGM Onset is on and that the pulse generator spends 3 months in Storage mode during shipping and storage.

a. Assumes ZIP telemetry use for 2 hours at implant and for 40 minutes annually for in-clinic follow-up checks.

b. Assumes standard use of the LATITUDE™ Communicator as follows: Daily Device Check on, quarterly scheduled remote follow ups, and other typical interrogations.

c. Assumes LATITUDE™ Communicator is not used, Respiratory Sensor is Off, and Heart Failure Sensor Suite is Off.

d. Applies to models with MultiSite Pacing (MSP). 


Additional Longevity Information

  • Boston Scientific devices have corporate warranties at 6 years in available geographies. Warranty information available at
  • Devices use Li/MnO2 chemistry.
  • The Usable Battery Capacity is 1.9 Amp-hours (typical implant to battery capacity depleted).
  • Shelf life is 2 years (before use by date).

Ordering information



C-Code: C1882
See all reimbursement resources

Education and training

Educational Resources
Explore CRT-D training and resources, best practices modules, medical training, and continuing education courses.

Register for EDUCARE


RESONATE CRT-D Indications, Safety and Warnings